changes in thyroid functional tests in breast cancer patients under tamoxifen therapy
Authors
abstract
abstract background: tamoxifen, a synthetic anti-estrogen agent, is administered as an adjuvant treatment in breast cancer. since various studies have indicated that tamoxifen can change some hormones and bound globolines, controversial results have been achieved using this medicine on thyroid functional tests (tft). the present study was conducted to investigate the effects of tamoxifen on tft in women with breast cancer referred to oncology clinic in imam hossein hospital between 2001 and 2002. method: a quasi-experimental clinical trial study was performed on 23 women with breast cancer in a single blind basis (with no control group). patients were under tamoxifen 20 mg p.o. daily and their serum tsh, free t4 and three iodothyronine (t3) were assessed before treatment with tamoxifen and after 3 months. paired t test was used for statistical analysis. results: there was a significant difference in t3 before and after the treatment with tamoxifen (p=0.02), whereas no significant differences were seen in tsh (p=0.095) and ft4 (p=0.13). discussion: this study showed that treatment with tamoxifen in women suffering from breast cancer results in an increase in serum t3 but has no effect on serum tsh and ft4, therefore women under treatment with tamoxifen remain euthyroid.
similar resources
Sonohysterography for evaluation of endometrial abnormalities in breast cancer patients under tamoxifen therapy
Introduction: Tamoxifen may have secondary adverse effects on the endometrium. The aim of this study was to investigate the endometrial evaluation in women with breast cancer under tamoxifen therapy with Saline infusion Sonohysterography (SIS). Materials and Methods: This cross-sectional study was performed on 40 breast cancer patients under adjutant tamoxifen (20 mg/day for at least 6 months) ...
full textValue of sonographic endometrial findings in patients with breast cancer under tamoxifen therapy
Tamoxifen is utilized as adjuvant therapy in women diagnosed with breast cancer. In these patients, despite its positive risk/benefit ratio, tamoxifen may cause secondary effects on the endometrium, with increased risk of malignant diseases. So, the first question to be answered is: “Does tamoxifen increase the incidence of endometrial abnormalities?” The literature presents two meta-analysis-s...
full textTreatment of Depression in Patients under Breast Cancer Therapy: Antidepressant-Tamoxifen Drug Interactions
The hormone therapy with tamoxifen is used in patients with breast cancer. The tamoxifen mechanism of action is based on the antagonist action of selective estrogen receptors. Depression and anxiety are psychiatric disorders which frequently coexist in patients with breast cancer. In the last decades, there has been an increase in the use of antidepressants. This literature review aims to provi...
full textBiochemistry of tamoxifen therapy in breast cancer.
Duncan, D. B. (1955) Biornetrics 11, 1-42 Gomez, E. C. & Frost, P. (1972) Ado. Biol. Skin 12,367-379 Hamilton, J. B. & Montagna, W. (1950) Am. J . Anot. 86, 191-233 Katchen, B. & Buxbaum, S. (1975) J . C/i/i. Etic/oci.i/io/. Metab. 41, 373-379 Liao, S., Howell, D. K. & Chang, T. (1974) Endocrinology 94, 1205-1208 Lutsky, B. N., Casmer, C. & Koziol, P. (1974) Lipid.x 9,43-48 Lutsky, B. N., Budak...
full textTamoxifen therapy in breast cancer control worldwide.
In most developed and many developing countries, breast cancer is the most frequent cancer and the leading cause of cancer death among women. At least 50% of all breast cancer patients worldwide would survive longer, however, if public awareness about and early detection of the condition were increased and greater use were made of efficient treatment of proven value. With early-stage, localized...
full textThyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer
Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months. Since all the patients obviously had residual l...
full textMy Resources
Save resource for easier access later
Journal title:
iranian journal of cancer preventionجلد ۱، شماره ۳، صفحات ۹۱-۹۳
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023